Boehringer Ingelheim International Gmbh

Lexicon Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Alexander Heim-Riether

Donghong Amy Gao

Zhaoming Xiong

Derek Cogan

Lana Louise Smith Keenan

Roger John Snow

Qiang Zhang

Craig Andrew Miller

Steven John Taylor

Philip Dean Ramsden

Yang Yu

Daniel R Goldberg

David John Augeri

Kenneth Gordon Carson

Jiang-Ping Wu

Marianne Carlsen

Asitha Abeywardane

Ingo Andreas Mugge

Qinghong Fu

Jerry Andrew Taylor

Shuang Liang

Sabine K Schlyer

Theodore C Jessop

James E Tarver

Neil Alexander Farrow

Yu Yang

Klaus Rudolf

Henri Doods

Eugene R Hickey

Dirk Stenkamp

Henning Priepke

Weimin Liu

Neil Moss

Roland Pfau

Dieter Wiedenmayer

Raimund Kuelzer

Rene Marc Lemieux

Alan David Swinamer

Michael Jason Burke

Zhidong Chen

Matthew Russell Netherton

Anil Kumar Padyana

Bernd Wellenzohn

Steven Richard Brunette

Matt Aaron Tschantz

Wang Mao

Bryan Patrick McKibben

Joerg Bentzien

Jennifer A Kowalski

Joshua Courtney Horan

Hui Yu

Jason Patrick Healy

David Charles Thompson

Michael David Lawlor

Kaka Dey

Antonio Jose Del Moral Barbosa, Jr

Xiaolian Xu

Min Shen

Philip E Keyes

John Edward Mangette

Younggi Choi

Bennett Farmer

Joerg Martin Bentzien

Bryan Mckibben

Donghong A Gao

Antonio Jose Del Moral Barbosa

Criag Andrew Miller

John E Mangette

The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A, A, A, L, Land D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds. 

Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase

Disclosed is a compound of formula (I). Wherein R, RAr and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I) to treat a disorder associated with activation of CCR10. 

[object Object]

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I. 

Heteroaryl substituted indole compounds useful as MMP-13 inhibitors

Disclosed are Cathepsin-S reversible inhibitor compounds of the formula (I) which are useful in the treatment of autoimmune and other diseases. Also disclosed are pharmaceutical compositions containing the same, and methods of making and using the same. 

Heteroaryl nitrile compounds useful as inhibitors of Cathepsin-S

This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin Esynthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R, R, R, R, R, R, R, R, Rhave meanings given in the description.

Compounds

Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I). 

Heteroaryl diamide compounds useful as MMP-13 inhibitors

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R, R, R. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10. 

2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10

Derivatives of 6,7-dihydro-5H-imidazo[1,2-&#x3b1;]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides

Fused heteroaryl diamide compounds useful as MMP-13 inhibitors

The invention relates to a compound of formula (I): or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein Rto R, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

CCR10 antagonists

4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed. Particular compounds are of formula I: 

4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use

O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described. Particular compounds of the invention are of formula I: 

O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer

Growing community of inventors

Newtown, CT, United States of America

Alexander Heim-Riether